Beam Therapeutics Granted FDA Orphan Drug Designation for BEAM-302 in Alpha-1 Antitrypsin Deficiency
Friday, May 30, 2025
Beam Therapeutics has announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a treatment candidate for alpha-1 antitrypsin deficiency (AATD).
AATD is an inherited disorder that primarily affects the lungs and liver. It can lead to early-onset emphysema and liver damage. Current treatment options are limited, with no cure currently available.
BEAM-302 is designed to correct the PiZ mutation, the most common and severe form of AATD. The approach aims to achieve a one-time A-to-G correction using an adenine base editor. This correction is intended to reduce harmful protein buildup in the liver, increase levels of functional AAT protein, and support the body's natural inflammatory response mechanisms.
By correcting the gene at its original location, the therapy may offer a durable solution that goes beyond the benefits of current protein replacement treatments.
The therapy uses a liver-targeting lipid nanoparticle (LNP) delivery system containing a guide RNA and an mRNA encoding a base editor, aiming to correct the genetic mutation responsible for the disease.
The FDA’s orphan drug designation is intended to encourage the development of treatments for rare diseases. It offers potential benefits such as tax credits for clinical trials, exemption from certain fees, and a possible seven-year market exclusivity following approval.
The therapy received clearance of its Investigational New Drug (IND) application in March 2025, and was also granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in May 2025.
It is estimated that around 100,000 individuals in the U.S. carry two copies of the Z allele, known as the PiZZ genotype. However, only about 10% of cases are currently diagnosed. The only approved treatment, intravenous AAT protein replacement, does not prevent the progressive damage to lung function seen in these patients.
BEAM-302 is being developed to address this unmet need.
Source: beamtx.com
